{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:01:47Z","timestamp":1771596107579,"version":"3.50.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Schizophrenia genome-wide association studies (GWASes) have identified &gt;250 significant loci and prioritized &gt;100 disease-related genes. However, gene prioritization efforts have mostly been restricted to locus-based methods that ignore information from the rest of the genome. To more accurately characterize genes involved in schizophrenia etiology, we applied a combination of highly-predictive tools to a published GWAS of 67,390 schizophrenia cases and 94,015 controls. We combined both locus-based methods (fine-mapped coding variants, distance to GWAS signals) and genome-wide methods (PoPS, MAGMA, ultra-rare coding variant burden tests). We extracted genes that 1) are targeted by existing drugs that could potentially be repurposed for schizophrenia, 2) are predicted to be druggable, or 3) may be testable in rodent models. We prioritized 101 schizophrenia genes, including 15 that are targeted by approved or investigational drugs (\n                    <jats:italic>e.g<\/jats:italic>\n                    .,\n                    <jats:italic>DRD2, GRIN2A<\/jats:italic>\n                    ,\n                    <jats:italic>CACNA1C, GABBR2<\/jats:italic>\n                    ). Of these, 7 have never been tested in clinical trials for schizophrenia or other psychiatric disorders (\n                    <jats:italic>e.g., AKT3<\/jats:italic>\n                    ). Seven genes are not targeted by any existing small molecule drugs, but are predicted to be druggable (\n                    <jats:italic>e.g., GRM1<\/jats:italic>\n                    ). We prioritized two potentially druggable genes in loci that are shared with an addiction GWAS (\n                    <jats:italic>PDE4B<\/jats:italic>\n                    and\n                    <jats:italic>VRK2<\/jats:italic>\n                    ). We curated a high-quality list of 101 genes that likely play a role in the development of schizophrenia. Developing or repurposing drugs that target these genes may lead to a new generation of schizophrenia therapies. Rodent models of addiction more closely resemble the human disorder than rodent models of schizophrenia. As such, genes prioritized for both disorders could be explored in rodent addiction models, potentially facilitating drug development.\n                  <\/jats:p>","DOI":"10.1038\/s41398-026-03813-0","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:48:33Z","timestamp":1770223713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying drug targets for schizophrenia through gene prioritization"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7306-1179","authenticated-orcid":false,"given":"Julia","family":"Kraft","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnil","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Panagiotaropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-2796","authenticated-orcid":false,"given":"Marijn","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0543-5623","authenticated-orcid":false,"given":"Nathaniel","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6845-7590","authenticated-orcid":false,"given":"Antonio F.","family":"Pardi\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-835X","authenticated-orcid":false,"given":"Stephan","family":"Ripke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4776-1723","authenticated-orcid":false,"given":"Karl","family":"Heilbron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Schizophrenia Working Group of the Psychiatric Genomics Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"3813_CR1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86\u201397.","journal-title":"Lancet"},{"key":"3813_CR2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2019.11.020","volume":"179","author":"Cross-Disorder Group of the Psychiatric Genomics Consortium.","year":"2019","unstructured":"Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address: plee0@mgh.harvard.edu, cross-disorder group of the psychiatric genomics consortium. genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179:1469\u2013.e11.","journal-title":"Cell"},{"key":"3813_CR3","volume":"12","author":"C Lu","year":"2022","unstructured":"Lu C, Jin D, Palmer N, Fox K, Kohane IS, Smoller JW, et al. Large-scale real-world data analysis identifies comorbidity patterns in schizophrenia. Transl Psychiatry. 2022;12:154.","journal-title":"Transl Psychiatry"},{"key":"3813_CR4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358.","journal-title":"Drug Alcohol Depend"},{"key":"3813_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","volume":"6","author":"SG Potkin","year":"2020","unstructured":"Potkin SG, Kane JM, Correll CU, Lindenmayer J-P, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. npj Schizophrenia. 2020;6:1\u201310.","journal-title":"npj Schizophrenia"},{"key":"3813_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","volume":"26","author":"MF Green","year":"2000","unstructured":"Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the \u2018right stuff\u2019?. Schizophr Bull. 2000;26:119\u201336.","journal-title":"Schizophr Bull"},{"key":"3813_CR7","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2147\/NDT.S201726","volume":"15","author":"G Cerveri","year":"2019","unstructured":"Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525\u201335.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3813_CR8","doi-asserted-by":"publisher","first-page":"105454","DOI":"10.1016\/j.neubiorev.2023.105454","volume":"155","author":"RTS Chow","year":"2023","unstructured":"Chow RTS, Whiting D, Favril L, Ostinelli E, Cipriani A, Fazel S. An umbrella review of adverse effects associated with antipsychotic medications: the need for complementary study designs. Neurosci Biobehav Rev. 2023;155:105454 https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105454.","journal-title":"Neurosci Biobehav Rev"},{"key":"3813_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.pnpbp.2017.11.004","volume":"82","author":"TSJ Iversen","year":"2018","unstructured":"Iversen TSJ, Steen NE, Dieset I, Hope S, M\u00f8rch R, Gardsjord ES, et al. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263\u201371. https:\/\/doi.org\/10.1016\/j.pnpbp.2017.11.004.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3813_CR10","first-page":"447","volume":"15","author":"A Mullard","year":"2016","unstructured":"Mullard A. Parsing clinical success rates. Nat Rev Drug Discov. 2016;15:447\u2013447.","journal-title":"Nat Rev Drug Discov"},{"key":"3813_CR11","doi-asserted-by":"publisher","unstructured":"Munro J, Dowden H. Trends in neuroscience dealmaking. Biopharma Dealmakers 2018. https:\/\/doi.org\/10.1038\/d43747-020-00598-z.","DOI":"10.1038\/d43747-020-00598-z"},{"key":"3813_CR12","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/d41573-023-00158-x","volume":"22","author":"PV Rusina","year":"2023","unstructured":"Rusina PV, Falaguera MJ, Romero JMR, McDonagh EM, Dunham I, Ochoa D. Genetic support for FDA-approved drugs over the past decade. Nat Rev Drug Discov. 2023;22:864.","journal-title":"Nat Rev Drug Discov"},{"key":"3813_CR13","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15:e1008489 https:\/\/doi.org\/10.1371\/journal.pgen.1008489.","journal-title":"PLoS Genet"},{"key":"3813_CR14","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856\u201360.","journal-title":"Nat Genet"},{"key":"3813_CR15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"S Ripke","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421.","journal-title":"Nature"},{"key":"3813_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41588-018-0059-2","volume":"50","author":"AF Pardi\u00f1as","year":"2018","unstructured":"Pardi\u00f1as AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50:381\u20139. https:\/\/doi.org\/10.1038\/s41588-018-0059-2.","journal-title":"Nat Genet"},{"key":"3813_CR17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","volume":"604","author":"V Trubetskoy","year":"2022","unstructured":"Trubetskoy V, Pardi\u00f1as AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604:502\u20138.","journal-title":"Nature"},{"key":"3813_CR18","doi-asserted-by":"crossref","unstructured":"Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024;629:624\u20139","DOI":"10.1038\/s41586-024-07316-0"},{"key":"3813_CR19","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ajhg.2022.07.011","volume":"109","author":"WR Reay","year":"2022","unstructured":"Reay WR, Geaghan MP, Atkins JR, Carr VJ, Green MJ, Cairns MJ. Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder. Am J Hum Genet. 2022;109:1620\u201337.","journal-title":"Am J Hum Genet"},{"key":"3813_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41588-021-00987-9","volume":"54","author":"B Zeng","year":"2022","unstructured":"Zeng B, Bendl J, Kosoy R, Fullard JF, Hoffman GE, Roussos P. Multi-ancestry eQTL meta-analysis of human brain identifies candidate causal variants for brain-related traits. Nat Genet. 2022;54:161\u20139.","journal-title":"Nat Genet"},{"key":"3813_CR21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41588-018-0092-1","volume":"50","author":"A Gusev","year":"2018","unstructured":"Gusev A, Mancuso N, Won H, Kousi M, Finucane HK, Reshef Y, et al. Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. Nat Genet. 2018;50:538\u201348.","journal-title":"Nat Genet"},{"key":"3813_CR22","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1016\/j.cell.2023.09.015","volume":"186","author":"CK Rummel","year":"2023","unstructured":"Rummel CK, Gagliardi M, Ahmad R, Herholt A, Jimenez-Barron L, Murek V, et al. Massively parallel functional dissection of schizophrenia-associated noncoding genetic variants. Cell. 2023;186:5165\u2013.e33.","journal-title":"Cell"},{"key":"3813_CR23","doi-asserted-by":"crossref","first-page":"eaat8127","DOI":"10.1126\/science.aat8127","volume":"362","author":"MJ Gandal","year":"2018","unstructured":"Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 2018;362:eaat8127.","journal-title":"Science"},{"key":"3813_CR24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41593-020-0603-0","volume":"23","author":"NYA Sey","year":"2020","unstructured":"Sey NYA, Hu B, Mah W, Fauni H, McAfee JC, Rajarajan P, et al. A computational tool (H-MAGMA) for improved prediction of brain-disorder risk genes by incorporating brain chromatin interaction profiles. Nat Neurosci. 2020;23:583\u201393.","journal-title":"Nat Neurosci"},{"key":"3813_CR25","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/bioinformatics\/btw018","volume":"32","author":"C Benner","year":"2016","unstructured":"Benner C, Spencer CCA, Havulinna AS, Salomaa V, Ripatti S, Pirinen M. FINEMAP: efficient variable selection using summary data from genome-wide association studies. Bioinformatics. 2016;32:1493\u2013501.","journal-title":"Bioinformatics"},{"key":"3813_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ng.3538","volume":"48","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48:481\u20137. https:\/\/doi.org\/10.1038\/ng.3538.","journal-title":"Nat Genet"},{"key":"3813_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ymeth.2012.05.001","volume":"58","author":"JM Belton","year":"2012","unstructured":"Belton JM, McCord RP, Gibcus JH, Naumova N, Zhan Y, Dekker J. Hi-C: a comprehensive technique to capture the conformation of genomes. Methods. 2012;58:268\u201376. https:\/\/doi.org\/10.1016\/j.ymeth.2012.05.001.","journal-title":"Methods"},{"key":"3813_CR28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41588-023-01443-6","volume":"55","author":"EM Weeks","year":"2023","unstructured":"Weeks EM, Ulirsch JC, Cheng NY, Trippe BL, Fine RS, Miao J, et al. Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. Nat Genet. 2023;55:1267\u201376.","journal-title":"Nat Genet"},{"key":"3813_CR29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","volume":"604","author":"T Singh","year":"2022","unstructured":"Singh T, Poterba T, Curtis D, Akil H, Al Eissa M, Barchas JD, et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022;604:509\u201316.","journal-title":"Nature"},{"key":"3813_CR30","doi-asserted-by":"crossref","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.","journal-title":"Gigascience"},{"key":"3813_CR31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ng.2213","volume":"44","author":"J Yang","year":"2012","unstructured":"Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 2012;44:369\u201375. S1\u20133.","journal-title":"Nat Genet"},{"key":"3813_CR32","doi-asserted-by":"crossref","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10:e1004383.","journal-title":"PLoS Genet"},{"key":"3813_CR33","doi-asserted-by":"crossref","first-page":"e1008720","DOI":"10.1371\/journal.pgen.1008720","volume":"16","author":"C Wallace","year":"2020","unstructured":"Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 2020;16:e1008720.","journal-title":"PLoS Genet"},{"key":"3813_CR34","doi-asserted-by":"crossref","first-page":"e1004219","DOI":"10.1371\/journal.pcbi.1004219","volume":"11","author":"CA de Leeuw","year":"2015","unstructured":"de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.","journal-title":"PLoS Comput Biol"},{"key":"3813_CR35","doi-asserted-by":"crossref","first-page":"D766","DOI":"10.1093\/nar\/gky955","volume":"47","author":"A Frankish","year":"2019","unstructured":"Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47:D766\u2013D773.","journal-title":"Nucleic Acids Res"},{"key":"3813_CR36","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/bioinformatics\/btq340","volume":"26","author":"CJ Willer","year":"2010","unstructured":"Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190\u20131.","journal-title":"Bioinformatics"},{"key":"3813_CR37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25\u201329.","journal-title":"Nat Genet"},{"key":"3813_CR38","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","volume":"39","author":"D Croft","year":"2011","unstructured":"Croft D, O\u2019Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2011;39:D691\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3813_CR39","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41588-020-00735-5","volume":"52","author":"O Weissbrod","year":"2020","unstructured":"Weissbrod O, Hormozdiari F, Benner C, Cui R, Ulirsch J, Gazal S, et al. Functionally informed fine-mapping and polygenic localization of complex trait heritability. Nat Genet. 2020;52:1355\u201363.","journal-title":"Nat Genet"},{"key":"3813_CR40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00281-021-00902-8","volume":"44","author":"QS Wang","year":"2022","unstructured":"Wang QS, Huang H. Methods for statistical fine-mapping and their applications to auto-immune diseases. Semin Immunopathol. 2022;44:101\u201313.","journal-title":"Semin Immunopathol"},{"key":"3813_CR41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285\u201391.","journal-title":"Nature"},{"key":"3813_CR42","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.cell.2019.12.036","volume":"180","author":"Satterstrom","year":"2020","unstructured":"Satterstrom, Kosmicki FK, Wang JA, Breen J, De MS, Rubeis S, An J-Y, et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell. 2020;180:568\u2013.e23.","journal-title":"Cell"},{"key":"3813_CR43","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41586-020-2832-5","volume":"586","author":"J Kaplanis","year":"2020","unstructured":"Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature. 2020;586:757\u201362.","journal-title":"Nature"},{"key":"3813_CR44","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1038\/s41380-022-01542-6","volume":"27","author":"M Wainberg","year":"2022","unstructured":"Wainberg M, Merico D, Keller MC, Fauman EB, Tripathy SJ. Predicting causal genes from psychiatric genome-wide association studies using high-level etiological knowledge. Mol Psychiatry. 2022;27:3095\u2013106.","journal-title":"Mol Psychiatry"},{"key":"3813_CR45","doi-asserted-by":"crossref","first-page":"D985","DOI":"10.1093\/nar\/gkw1055","volume":"45","author":"G Koscielny","year":"2017","unstructured":"Koscielny G, An P, Carvalho-Silva D, Cham JA, Fumis L, Gasparyan R, et al. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res. 2017;45:D985\u2013D994.","journal-title":"Nucleic Acids Res"},{"key":"3813_CR46","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s44220-023-00034-y","volume":"1","author":"AS Hatoum","year":"2023","unstructured":"Hatoum AS, Colbert SMC, Johnson EC, Huggett SB, Deak JD, Pathak G, et al. Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. Nat Ment Health. 2023;1:210\u201323.","journal-title":"Nat Ment Health"},{"key":"3813_CR47","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091\u2013102.","journal-title":"Lancet Neurol"},{"key":"3813_CR48","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/s41380-022-01490-1","volume":"27","author":"RG Mealer","year":"2022","unstructured":"Mealer RG, Williams SE, Noel M, Yang B, D\u2019Souza AK, Nakata T, et al. The schizophrenia-associated variant in SLC39A8 alters protein glycosylation in the mouse brain. Mol Psychiatry. 2022;27:1405\u201315.","journal-title":"Mol Psychiatry"},{"key":"3813_CR49","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00406-022-01409-5","volume":"272","author":"A Hatzimanolis","year":"2022","unstructured":"Hatzimanolis A, Foteli S, Stefanatou P, Ntigrintaki A-A, Ralli I, Kollias K, et al. Deregulation of complement components C4A and CSMD1 peripheral expression in first-episode psychosis and links to cognitive ability. Eur Arch Psychiatry Clin Neurosci. 2022;272:1219\u201328.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3813_CR50","doi-asserted-by":"crossref","first-page":"e79501","DOI":"10.1371\/journal.pone.0079501","volume":"8","author":"VM Steen","year":"2013","unstructured":"Steen VM, Nepal C, Ersland KM, Holdhus R, N\u00e6vdal M, Ratvik SM, et al. Neuropsychological deficits in mice depleted of the schizophrenia susceptibility gene CSMD1. PLoS One. 2013;8:e79501.","journal-title":"PLoS One"},{"key":"3813_CR51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature25758","volume":"555","author":"S Wang","year":"2018","unstructured":"Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature. 2018;555:269\u201373.","journal-title":"Nature"},{"key":"3813_CR52","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/j.neuron.2024.08.005","volume":"112","author":"C Borcuk","year":"2024","unstructured":"Borcuk C, Parihar M, Sportelli L, Kleinman JE, Shin JH, Hyde TM, et al. Network-wide risk convergence in gene co-expression identifies reproducible genetic hubs of schizophrenia risk. Neuron. 2024;112:3551\u2013.e6.","journal-title":"Neuron"},{"key":"3813_CR53","doi-asserted-by":"crossref","first-page":"eade2812","DOI":"10.1126\/sciadv.ade2812","volume":"9","author":"G Pergola","year":"2023","unstructured":"Pergola G, Parihar M, Sportelli L, Bharadwaj R, Borcuk C, Radulescu E, et al. Consensus molecular environment of schizophrenia risk genes in coexpression networks shifting across age and brain regions. Sci Adv. 2023;9:eade2812.","journal-title":"Sci Adv"},{"key":"3813_CR54","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/s41588-023-01560-2","volume":"55","author":"A Bhattacharya","year":"2023","unstructured":"Bhattacharya A, Vo DD, Jops C, Kim M, Wen C, Hervoso JL, et al. Isoform-level transcriptome-wide association uncovers genetic risk mechanisms for neuropsychiatric disorders in the human brain. Nat Genet. 2023;55:2117\u201328.","journal-title":"Nat Genet"},{"key":"3813_CR55","doi-asserted-by":"crossref","unstructured":"Deans PJM, Townsley KG, Li A, Seah C, Johnson J, Gonzalez JG et al. Convergent and non-additive impact of schizophrenia risk genes in human neurons. bioRxiv. 2022; 2022.03.29.486286.","DOI":"10.1101\/2022.03.29.486286"},{"key":"3813_CR56","volume":"3","author":"JC McAfee","year":"2023","unstructured":"McAfee JC, Lee S, Lee J, Bell JL, Krupa O, Davis J, et al. Systematic investigation of allelic regulatory activity of schizophrenia-associated common variants. Cell Genom. 2023;3:100404.","journal-title":"Cell Genom"},{"key":"3813_CR57","doi-asserted-by":"publisher","first-page":"eaat4311","DOI":"10.1126\/science.aat4311","volume":"362","author":"P Rajarajan","year":"2018","unstructured":"Rajarajan P, Borrman T, Liao W, Schrode N, Flaherty E, Casi\u00f1o C, et al. Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk. Science. 2018;362:eaat4311 https:\/\/doi.org\/10.1126\/science.aat4311.","journal-title":"Science"},{"key":"3813_CR58","doi-asserted-by":"publisher","first-page":"eaag1166","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9:eaag1166 https:\/\/doi.org\/10.1126\/scitranslmed.aag1166.","journal-title":"Sci Transl Med"},{"key":"3813_CR59","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41593-019-0382-7","volume":"22","author":"Q Wang","year":"2019","unstructured":"Wang Q, Chen R, Cheng F, Wei Q, Ji Y, Yang H, et al. A Bayesian framework that integrates multi-omics data and gene networks predicts risk genes from schizophrenia GWAS data. Nat Neurosci. 2019;22:691\u20139.","journal-title":"Nat Neurosci"},{"key":"3813_CR60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41525-022-00290-4","volume":"7","author":"SG Lago","year":"2022","unstructured":"Lago SG, Bahn S. The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. NPJ Genom Med. 2022;7:25.","journal-title":"NPJ Genom Med"},{"key":"3813_CR61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48307-w","volume":"9","author":"KB Karunakaran","year":"2019","unstructured":"Karunakaran KB, Chaparala S, Ganapathiraju MK. Potentially repurposable drugs for schizophrenia identified from its interactome. Sci Rep. 2019;9:12682.","journal-title":"Sci Rep"},{"key":"3813_CR62","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1016\/j.neuron.2023.08.004","volume":"111","author":"Z Farsi","year":"2023","unstructured":"Farsi Z, Nicolella A, Simmons SK, Aryal S, Shepard N, Brenner K, et al. Brain-region-specific changes in neurons and glia and dysregulation of dopamine signaling in Grin2a mutant mice. Neuron. 2023;111:3378\u2013.e9.","journal-title":"Neuron"},{"key":"3813_CR63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44443-6","volume":"13","author":"S Wasserthal","year":"2023","unstructured":"Wasserthal S, Lehmann M, Neumann C, Delis A, Philipsen A, Hurlemann R, et al. Effects of NMDA-receptor blockade by ketamine on mentalizing and its neural correlates in humans: a randomized control trial. Sci Rep. 2023;13:17184.","journal-title":"Sci Rep"},{"key":"3813_CR64","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/0269881120965937","volume":"35","author":"KK Goh","year":"2021","unstructured":"Goh KK, Wu T-H, Chen C-H, Lu M-L. Efficacy of -methyl-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials. J Psychopharmacol. 2021;35:236\u201352.","journal-title":"J Psychopharmacol"},{"key":"3813_CR65","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/biom12070909","volume":"12","author":"A de Bartolomeis","year":"2022","unstructured":"de Bartolomeis A, Vellucci L, Austin MC, De Simone G, Barone A. Rational and translational implications of D-amino acids for treatment-resistant schizophrenia: from neurobiology to the clinics. Biomolecules. 2022;12:909 https:\/\/doi.org\/10.3390\/biom12070909.","journal-title":"Biomolecules"},{"key":"3813_CR66","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","volume":"273","author":"H Rosenbrock","year":"2023","unstructured":"Rosenbrock H, Desch M, Wunderlich G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273:1557\u201366.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3813_CR67","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173493","volume":"221","author":"S Dogra","year":"2022","unstructured":"Dogra S, Putnam J, Conn PJ. Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders. Pharmacol Biochem Behav. 2022;221:173493.","journal-title":"Pharmacol Biochem Behav"},{"key":"3813_CR68","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-014-0351-3","volume":"14","author":"AM Downing","year":"2014","unstructured":"Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014;14:351.","journal-title":"BMC Psychiatry"},{"key":"3813_CR69","doi-asserted-by":"crossref","first-page":"758212","DOI":"10.1155\/2014\/758212","volume":"2014","author":"DH Adams","year":"2014","unstructured":"Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez J-C. Pomaglumetad methionil (LY2140023 Monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr Res Treatment. 2014;2014:758212.","journal-title":"Schizophr Res Treatment"},{"key":"3813_CR70","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","volume":"31","author":"BJ Kinon","year":"2011","unstructured":"Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31:349\u201355.","journal-title":"J Clin Psychopharmacol"},{"key":"3813_CR71","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"ST Patil","year":"2007","unstructured":"Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102\u20137.","journal-title":"Nat Med"},{"key":"3813_CR72","doi-asserted-by":"publisher","unstructured":"Kinon BJ, Millen BA, Zhang L, McKinzie DL Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry 2015; 78: 754-62. https:\/\/doi.org\/10.1016\/j.biopsych.2015.03.016","DOI":"10.1016\/j.biopsych.2015.03.016"},{"key":"3813_CR73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.biopsych.2021.02.970","volume":"90","author":"S Dogra","year":"2021","unstructured":"Dogra S, Stansley BJ, Xiang Z, Qian W, Gogliotti RG, Nicoletti F, et al. Activating mGlu metabotropic glutamate receptors rescues schizophrenia-like cognitive deficits through metaplastic adaptations within the hippocampus. Biol Psychiatry. 2021;90:385\u201398.","journal-title":"Biol Psychiatry"},{"key":"3813_CR74","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/cercor\/bhx005","volume":"28","author":"LE Jin","year":"2018","unstructured":"Jin LE, Wang M, Galvin VC, Lightbourne TC, Conn PJ, Arnsten AFT, et al. mGluR2 versus mGluR3 metabotropic glutamate receptors in primate dorsolateral prefrontal cortex: postsynaptic mGluR3 strengthen working memory networks. Cereb Cortex. 2018;28:974\u201387.","journal-title":"Cereb Cortex"},{"key":"3813_CR75","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109950","volume":"37","author":"J Maksymetz","year":"2021","unstructured":"Maksymetz J, Byun NE, Luessen DJ, Li B, Barry RL, Gore JC, et al. mGlu potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits. Cell Rep. 2021;37:109950.","journal-title":"Cell Rep"},{"key":"3813_CR76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coph.2018.02.003","volume":"38","author":"BJ Stansley","year":"2018","unstructured":"Stansley BJ, Conn PJ. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. Curr Opin Pharmacol. 2018;38:31\u201336.","journal-title":"Curr Opin Pharmacol"},{"key":"3813_CR77","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/s41380-018-0206-2","volume":"25","author":"SE Yohn","year":"2020","unstructured":"Yohn SE, Foster DJ, Covey DP, Moehle MS, Galbraith J, Garcia-Barrantes PM, et al. Activation of the mGlu metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M muscarinic receptor allosteric modulators. Mol Psychiatry. 2020;25:2786\u201399.","journal-title":"Mol Psychiatry"},{"key":"3813_CR78","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","volume":"96","author":"SM Paul","year":"2024","unstructured":"Paul SM, Yohn SE, Brannan SK, Neugebauer NM, Breier A. Muscarinic receptor activators as novel treatments for schizophrenia. Biol Psychiatry. 2024;96:627\u201337.","journal-title":"Biol Psychiatry"},{"key":"3813_CR79","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1399-5618.2008.00636.x","volume":"10","author":"AG Mallinger","year":"2008","unstructured":"Mallinger AG, Thase ME, Haskett R, Buttenfield J, Luckenbaugh DA, Frank E, et al. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord. 2008;10:856\u201366.","journal-title":"Bipolar Disord"},{"key":"3813_CR80","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41588-021-00857-4","volume":"53","author":"N Mullins","year":"2021","unstructured":"Mullins N, Forstner AJ, O\u2019Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53:817\u201329.","journal-title":"Nat Genet"},{"key":"3813_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-020-00135-y","volume":"7","author":"J Lintunen","year":"2021","unstructured":"Lintunen J, L\u00e4hteenvuo M, Tiihonen J, Tanskanen A, Taipale H. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia. NPJ Schizophr. 2021;7:1.","journal-title":"NPJ Schizophr"},{"key":"3813_CR82","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/JCP.0000000000001274","volume":"40","author":"B Vahdani","year":"2020","unstructured":"Vahdani B, Armani KA, Esmaeilzadeh A, Zenoozian S, Yousefi V, Mazloomzadeh S. Adjunctive Raloxifene and isradipine improve cognitive functioning in patients with schizophrenia: a pilot study. J Clin Psychopharmacol. 2020;40:457\u201363. https:\/\/doi.org\/10.1097\/JCP.0000000000001274.","journal-title":"J Clin Psychopharmacol"},{"key":"3813_CR83","volume":"10","author":"CF Zink","year":"2020","unstructured":"Zink CF, Giegerich M, Prettyman GE, Carta KE, van Ginkel M, O\u2019Rourke MP, et al. Nimodipine improves cortical efficiency during working memory in healthy subjects. Transl Psychiatry. 2020;10:372.","journal-title":"Transl Psychiatry"},{"key":"3813_CR84","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/hup.2289","volume":"28","author":"MF Egan","year":"2013","unstructured":"Egan MF, Zhao X, Smith A, Troyer MD, Uebele VN, Pidkorytov V, et al. Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia. Hum Psychopharmacol. 2013;28:124\u201333.","journal-title":"Hum Psychopharmacol"},{"key":"3813_CR85","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-02186-4","volume":"12","author":"LA Greco","year":"2022","unstructured":"Greco LA, Reay WR, Dayas CV, Cairns MJ. Pairwise genetic meta-analyses between schizophrenia and substance dependence phenotypes reveals novel association signals with pharmacological significance. Transl Psychiatry. 2022;12:403.","journal-title":"Transl Psychiatry"},{"key":"3813_CR86","doi-asserted-by":"crossref","first-page":"247","DOI":"10.31887\/DCNS.2017.19.3\/rspanagel","volume":"19","author":"R Spanagel","year":"2017","unstructured":"Spanagel R. Animal models of addiction. Dialogues Clin Neurosci. 2017;19:247\u201358.","journal-title":"Dialogues Clin Neurosci"},{"key":"3813_CR87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejim.2022.05.016","volume":"103","author":"M Antonelli","year":"2022","unstructured":"Antonelli M, Sestito L, Tarli C, Addolorato G. Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?. Eur J Intern Med. 2022;103:13\u201322.","journal-title":"Eur J Intern Med"},{"key":"3813_CR88","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/adb.12106","volume":"20","author":"RL Bell","year":"2015","unstructured":"Bell RL, Lopez MF, Cui C, Egli M, Johnson KW, Franklin KM, et al. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol. 2015;20:38\u201342.","journal-title":"Addict Biol"},{"key":"3813_CR89","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01478-5","volume":"11","author":"EN Grodin","year":"2021","unstructured":"Grodin EN, Bujarski S, Towns B, Burnette E, Nieto S, Lim A, et al. Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. Transl Psychiatry. 2021;11:355.","journal-title":"Transl Psychiatry"},{"key":"3813_CR90","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00213-018-5134-y","volume":"238","author":"J Gilleen","year":"2021","unstructured":"Gilleen J, Farah Y, Davison C, Kerins S, Valdearenas L, Uz T, et al. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology (Berl). 2021;238:1279\u201389.","journal-title":"Psychopharmacology (Berl)"},{"key":"3813_CR91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1192\/bjp.bp.115.161950","volume":"209","author":"M Tesli","year":"2016","unstructured":"Tesli M, Wirgenes KV, Hughes T, Bettella F, Athanasiu L, Hoseth ES, et al. VRK2 gene expression in schizophrenia, bipolar disorder and healthy controls. Br J Psychiatry. 2016;209:114\u201320.","journal-title":"Br J Psychiatry"},{"key":"3813_CR92","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/glia.23638","volume":"67","author":"J Lee","year":"2019","unstructured":"Lee J, Lee S, Ryu Y-J, Lee D, Kim S, Seo J-Y, et al. Vaccinia-related kinase 2 plays a critical role in microglia-mediated synapse elimination during neurodevelopment. Glia. 2019;67:1667\u201379.","journal-title":"Glia"},{"key":"3813_CR93","doi-asserted-by":"crossref","first-page":"D1353","DOI":"10.1093\/nar\/gkac1046","volume":"51","author":"D Ochoa","year":"2023","unstructured":"Ochoa D, Hercules A, Carmona M, Suveges D, Baker J, Malangone C, et al. The next-generation open targets platform: reimagined, redesigned, rebuilt. Nucleic Acids Res. 2023;51:D1353\u2013D1359.","journal-title":"Nucleic Acids Res"},{"key":"3813_CR94","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.701729","volume":"12","author":"M Parellada","year":"2021","unstructured":"Parellada M, San Jos\u00e9 C\u00e1ceres A, Palmer M, Delorme R, Jones EJH, Parr JR, et al. A Phase II randomized, double-blind, placebo-controlled Study of the efficacy, safety, and tolerability of arbaclofen administered for the treatment of social function in children and adolescents with autism spectrum disorders: Study protocol for AIMS-2-TRIALS-CT1. Front Psychiatry. 2021;12:701729.","journal-title":"Front Psychiatry"},{"key":"3813_CR95","doi-asserted-by":"publisher","first-page":"e37799","DOI":"10.7554\/eLife.37799","volume":"7","author":"Grent-\u2019t-Jong T","year":"2018","unstructured":"Grent-\u2019t-Jong T, Gross J, Goense J, Wibral M, Gajwani R, Gumley AI, et al. Resting-state gamma-band power alterations in schizophrenia reveal E\/I-balance abnormalities across illness-stages. eLife. 2018;7:e37799 https:\/\/doi.org\/10.7554\/eLife.37799.","journal-title":"eLife"},{"key":"3813_CR96","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.schres.2010.12.025","volume":"128","author":"SH Fatemi","year":"2011","unstructured":"Fatemi SH, Folsom TD, Thuras PD. Deficits in GABA(B) receptor system in schizophrenia and mood disorders: a postmortem study. Schizophr Res. 2011;128:37\u201343.","journal-title":"Schizophr Res"},{"key":"3813_CR97","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/mp.2017.25","volume":"23","author":"F Orhan","year":"2018","unstructured":"Orhan F, Fatouros-Bergman H, Goiny M, Malmqvist A, Piehl F, Karolinska Schizophrenia Project (KaSP) Consortium, et al. CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Mol Psychiatry. 2018;23:1244\u201350.","journal-title":"Mol Psychiatry"},{"key":"3813_CR98","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/schbul\/sbs092","volume":"39","author":"LM Rowland","year":"2013","unstructured":"Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA, et al. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull. 2013;39:1096\u2013104.","journal-title":"Schizophr Bull"},{"key":"3813_CR99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2017.07.021","volume":"193","author":"PW Chiu","year":"2018","unstructured":"Chiu PW, Lui SSY, Hung KSY, Chan RCK, Chan Q, Sham PC, et al. In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study. Schizophr Res. 2018;193:295\u2013303.","journal-title":"Schizophr Res"},{"key":"3813_CR100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fpsyt.2019.00078","volume":"10","author":"F De Crescenzo","year":"2019","unstructured":"De Crescenzo F, Postorino V, Siracusano M, Riccioni A, Armando M, Curatolo P, et al. Autistic symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis. Front Psychiatry. 2019;10:78.","journal-title":"Front Psychiatry"},{"key":"3813_CR101","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2020.3908","volume":"78","author":"LD Oliver","year":"2021","unstructured":"Oliver LD, Moxon-Emre I, Lai MC, Grennan L, Voineskos AN, Ameis SH. Social cognitive performance in schizophrenia spectrum disorders compared with autism spectrum disorder: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2021;78:281\u201392. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3908.","journal-title":"JAMA Psychiatry"},{"key":"3813_CR102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/d41573-023-00202-w","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. FDA approves first-in-class AKT inhibitor. Nat Rev Drug Discov. 2024;23:9.","journal-title":"Nat Rev Drug Discov"},{"key":"3813_CR103","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13578-022-00793-8","volume":"12","author":"A-M Tsimberidou","year":"2022","unstructured":"Tsimberidou A-M, Skliris A, Valentine A, Shaw J, Hering U, Vo HH, et al. AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology. Cell Biosci. 2022;12:56.","journal-title":"Cell Biosci"},{"key":"3813_CR104","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fnmol.2017.00102","volume":"10","author":"Y Bergeron","year":"2017","unstructured":"Bergeron Y, Bureau G, Laurier-Laurin M-\u00c9, Asselin E, Massicotte G, Cyr M. Genetic Deletion of Akt3 Induces an Endophenotype Reminiscent of Psychiatric Manifestations in Mice. Front Mol Neurosci. 2017;10:102.","journal-title":"Front Mol Neurosci"},{"key":"3813_CR105","doi-asserted-by":"crossref","first-page":"e0175993","DOI":"10.1371\/journal.pone.0175993","volume":"12","author":"KR Howell","year":"2017","unstructured":"Howell KR, Floyd K, Law AJ. PKB\u03b3\/AKT3 loss-of-function causes learning and memory deficits and deregulation of AKT\/mTORC2 signaling: Relevance for schizophrenia. PLoS One. 2017;12:e0175993.","journal-title":"PLoS One"},{"key":"3813_CR106","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, et al. Trial of cinpanemab in early parkinson\u2019s disease. N Engl J Med. 2022;387:408\u201320.","journal-title":"N Engl J Med"},{"key":"3813_CR107","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of prasinezumab in early-stage parkinson\u2019s disease. N Engl J Med. 2022;387:421\u201332.","journal-title":"N Engl J Med"},{"key":"3813_CR108","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature17939","volume":"533","author":"F Soldner","year":"2016","unstructured":"Soldner F, Stelzer Y, Shivalila CS, Abraham BJ, Latourelle JC, Barrasa MI, et al. Parkinson-associated risk variant in distal enhancer of \u03b1-synuclein modulates target gene expression. Nature. 2016;533:95\u201399.","journal-title":"Nature"},{"key":"3813_CR109","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41588-023-01529-1","volume":"55","author":"H Mostafavi","year":"2023","unstructured":"Mostafavi H, Spence JP, Naqvi S, Pritchard JK. Systematic differences in discovery of genetic effects on gene expression and complex traits. Nat Genet. 2023;55:1866\u201375.","journal-title":"Nat Genet"},{"key":"3813_CR110","doi-asserted-by":"publisher","first-page":"100210","DOI":"10.1016\/j.xgen.2022.100210","volume":"2","author":"M Kanai","year":"2022","unstructured":"Kanai M, Elzur R, Zhou W, Global Biobank Meta-analysis Initiative, Daly MJ, Finucane HK. Meta-analysis fine-mapping is often miscalibrated at single-variant resolution. Cell Genom. 2022;2:100210 https:\/\/doi.org\/10.1016\/j.xgen.2022.100210.","journal-title":"Cell Genom"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03813-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03813-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03813-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:03:09Z","timestamp":1771592589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-03813-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-03813-0","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JK, AB, SA, GP, MS, NB, DP, and SR have nothing to disclose. AFP reports receiving a grant from Akrivia Health for a project unrelated to this submission. KH is a former employee of 23andMe, Inc. and owns 23andMe, Inc. stock options.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}